For: | Farkas K, Lakatos PL, Szűcs M, Pallagi-Kunstár &, Bálint A, Nagy F, Szepes Z, Vass N, Kiss LS, Wittmann T, Molnár T. Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20(11): 2995-3001 [PMID: 24659890 DOI: 10.3748/wjg.v20.i11.2995] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i11/2995.htm |
Number | Citing Articles |
1 |
Carmen Muñoz Villafranca, Maria Teresa Bravo Rodríguez, Jone Ortiz de Zárate, Paz Arreba González, Iñigo García Kamiruaga, Juan Ignacio Heras Martín, Pilar Cabezudo Gil, Víctor Orive Cura. Evolución clínica tras la suspensión de infliximab en pacientes con colitis ulcerosa en remisión profunda. Gastroenterología y Hepatología 2016; 39(7): 442 doi: 10.1016/j.gastrohep.2015.11.011
|
2 |
Caroline Klotz, Maximilien Barret, Marion Dhooge, Ammar Oudjit, Stanislas Chaussade, Romain Coriat, Vered Abitbol. Rectocolite hémorragique : conduite diagnostique et prise en charge thérapeutique. La Presse Médicale 2015; 44(2): 144 doi: 10.1016/j.lpm.2014.06.025
|
3 |
Giovanni C Actis. Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Annals of Colorectal Research 2016; (Inpress) doi: 10.17795/acr-42868
|
4 |
Thomas P Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020; 5(1): 63 doi: 10.1016/S2468-1253(19)30186-4
|
5 |
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D’Haens, Annemarie C. de Vries, Annemarie C. de Vries, Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Jasmijn A.M. Sleutjes, Marjolijn Duijvestein, Geert R. D’Haens, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, José M. García-Ortiz, Robert Downey, Alenka J. Brooks, Peter J. Hamlin, Shaji Sebastian, Alan J. Lobo, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Levinus (Leo) A. Dieleman, Xavier Roblin, Shomron Ben-Horin, Klaudia Farkas, Jakob B. Seidelin, Casper Steenholdt, Steven Bots. Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology 2022; 20(8): 1671 doi: 10.1016/j.cgh.2021.03.037
|
6 |
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen, Jean-Frédéric Colombel. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database of Systematic Reviews 2018; 2018(5) doi: 10.1002/14651858.CD012540.pub2
|
7 |
Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz, Péter L. Lakatos. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues 2016; 10: 85 doi: 10.1016/j.vhri.2016.07.004
|
8 |
Kunio Asonuma, Keiji Ozeki, Hajime Yamazaki, Shinji Okabayashi, Soh Okano, Ryo Ozaki, Nobuaki Nishimata, Hiroki Kiyohara, Naoki Ichinari, Taku Kobayashi, Masahiro Yamada, Mao Matsubayashi, Yoko Yokoyama, Shoko Arimitsu, Junji Umeno, Yoshinori Munetomo, Akira Andoh, Shinichiro Shinzaki. Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study. Journal of Gastroenterology and Hepatology 2024; 39(1): 66 doi: 10.1111/jgh.16376
|
9 |
Robert P. Hirten, Peter L. Lakatos, Jonas Halfvarson, Jean Frederic Colombel. A User’s Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2020; 18(6): 1336 doi: 10.1016/j.cgh.2019.12.019
|
10 |
Zixi Jia, Yilu Wang, Shengming Li, Meiqi Yang, Zhongyuan Liu, Huijing Zhang. MICDnet: Multimodal information processing networks for Crohn’s disease diagnosis. Computers in Biology and Medicine 2024; 168: 107790 doi: 10.1016/j.compbiomed.2023.107790
|
11 |
Gionata Fiorino, Pablo Navarro Cortes, Pierre Ellul, Carla Felice, Pantelis Karatzas, Marco Silva, Peter L. Lakatos, Fabrizio Bossa, Bella Ungar, Shaji Sebastian, Federica Furfaro, Konstantinos Karmiris, Konstantinos H. Katsanos, Martina Muscat, Dimitrios K. Christodoulou, Giovanni Maconi, Uri Kopylov, Fernando Magro, Gerassimos J. Mantzaris, Alessandro Armuzzi, Marta Maia Boscà-Watts, Shomron Ben-Horin, Stefanos Bonovas, Silvio Danese. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology 2016; 14(10): 1426 doi: 10.1016/j.cgh.2016.05.044
|
12 |
J. P. Gisbert, A. C. Marín, M. Chaparro. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy. Alimentary Pharmacology & Therapeutics 2015; 42(4): 391 doi: 10.1111/apt.13276
|
13 |
Carmen Muñoz Villafranca, Maria Teresa Bravo Rodríguez, Jone Ortiz de Zárate, Paz Arreba González, Iñigo García Kamiruaga, Juan Ignacio Heras Martín, Pilar Cabezudo Gil, Víctor Orive Cura. Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission. Gastroenterología y Hepatología (English Edition) 2016; 39(7): 442 doi: 10.1016/j.gastre.2016.06.012
|
14 |
Hai Yun Shi, Francis K. L. Chan, Steven W. C. Tsang, Yee Tak Hui, Shun Fung Sze, Jessica Y. L. Ching, Tiffany Chung, Catherine Y. Y. Iu, Fu Hang Lo, Edwin H. S. Shan, Michael K. K. Li, Justin C. Y. Wu, Joseph J. Y. Sung, Siew C. Ng. Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission. Inflammatory Bowel Diseases 2015; 21(4): 840 doi: 10.1097/MIB.0000000000000334
|
15 |
Javier P Gisbert, Alicia C Marín, María Chaparro. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2016; 111(5): 632 doi: 10.1038/ajg.2016.54
|
16 |
David B. Alexander, Masaaki Iigo, Mohamed Abdelgied, Keiji Ozeki, Satoshi Tanida, Takashi Joh, Satoru Takahashi, Hiroyuki Tsuda. Bovine lactoferrin and Crohn’s disease: a case study. Biochemistry and Cell Biology 2017; 95(1): 133 doi: 10.1139/bcb-2016-0107
|
17 |
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149(7): 1716 doi: 10.1053/j.gastro.2015.08.055
|
18 |
Takashi Taida, Makoto Arai, Mai Fujie, Naoki Akizue, Kentaro Ishikawa, Yuki Ohta, Shinsaku Hamanaka, Hideaki Ishigami, Kenichiro Okimoto, Keiko Saito, Daisuke Maruoka, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Naoya Kato. Real-time Endoscopy-Guided Measurement of Rectal Mucosal Admittance Is a Novel and Safe Method for Predicting Ulcerative Colitis Relapse. Inflammatory Bowel Diseases 2018; 24(11): 2360 doi: 10.1093/ibd/izy191
|
19 |
Fabio Salvatore Macaluso, Sara Renna, Ambrogio Orlando, Mario Cottone. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2017; 17(2): 175 doi: 10.1080/14712598.2017.1271871
|
20 |
Javier P. Gisbert, Manuel Barreiro-de Acosta, María Esteve, Valle García-Sánchez, Fernando Gomollón, Jordi Guardiola, Joaquin Hinojosa, Maria-Dolores Martín Arranz, Miguel Minguez, Carlos Taxonera, Isabel Vera. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis. Inflammatory Bowel Diseases 2016; 22(3): 583 doi: 10.1097/MIB.0000000000000617
|
21 |
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis. European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018; 12(1): 17 doi: 10.1093/ecco-jcc/jjx101
|
22 |
Klaudia Farkas, Mariann Rutka, Petra A. Golovics, Zsuzsanna Végh, Barbara D. Lovász, Tibor Nyári, Krisztina B. Gecse, Martin Kolar, Martin Bortlik, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malickova, Anita Bálint, Ferenc Nagy, Renáta Bor, Ágnes Milassin, Zoltán Szepes, Károly Palatka, Péter L. Lakatos, Milan Lukas, Tamás Molnár. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. Journal of Crohn's and Colitis 2016; 10(11): 1273 doi: 10.1093/ecco-jcc/jjw085
|
23 |
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2021; 6(6): 429 doi: 10.1016/S2468-1253(21)00062-5
|
24 |
M J Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, M Rojas-Feria, A Jauregui-Amezaga, S García-López, J M Huguet, F Arguelles-Arias, M Aicart, I Marín-Jiménez, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, J Tosca, J R Pineda, M Mañosa, J Llaó, J Guardiola, I Pérez-Martínez, C Muñoz, Y González-Lama, J Hinojosa, J M Vázquez, M P Martinez-Montiel, G E Rodríguez, R Pajares, M F García-Sepulcre, A Hernández-Martínez, J L Pérez-Calle, B Beltrán, D Busquets, L Ramos, F Bermejo, J Barrio, M Barreiro-de Acosta, O Roncedo, X Calvet, D Hervías, F Gomollón, M Domínguez-Antonaya, G Alcaín, B Sicilia, C Dueñas, A Gutiérrez, R Lorente-Poyatos, M Domínguez, S Khorrami, C Taxonera, A Rodríguez-Pérez, A Ponferrada, M Van Domselaar, M L Arias-Rivera, O Merino, E Castro, J M Marrero, M Martín-Arranz, B Botella, L Fernández-Salazar, D Monfort, V Opio, A García-Herola, M Menacho, Ramírez-de P la Piscina, D Ceballos, P Almela, M Navarro-Llavat, V Robles-Alonso, A B Vega-López, I Moraleja, M T Novella, C Castaño-Milla, A Sánchez-Torres, J M Benítez, C Rodríguez, L Castro, E Garrido, E Domènech, E García-Planella, J P Gisbert. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology 2017; 112(1): 120 doi: 10.1038/ajg.2016.569
|
25 |
Giovanni C Actis. Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Annals of Colorectal Research 2016; 5(1) doi: 10.5812/acr.42868
|
26 |
Hang Hock Shim, Cynthia H. Seow. Treatment of Inflammatory Bowel Disease with Biologics. 2018; : 141 doi: 10.1007/978-3-319-60276-9_10
|
27 |
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395
|